| 1. |
Yuan B. Towards a clinical efficacy evaluation system adapted for personalized medicine. Pharmgenomics Pers Med, 2021, 14: 487-496.
|
| 2. |
吳家睿. 精確醫學5年歷程的回顧與思考(上). 醫學與哲學, 2021, 42(20): 1-4,10.
|
| 3. |
Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and.
|
| 4. |
于亞南, 杜培艷, 劉駿, 等. 精準醫學創新性臨床試驗設計“主方案”研究的概念, 設計與案例. 中國新藥雜志, 2020, 29(23): 2712-2717.
|
| 5. |
高珺, 蘇麗文, 袁鷹, 等. 抗腫瘤藥物主方案試驗設計進展及統計考量. 中國衛生統計, 2021, 38(6): 950-955.
|
| 6. |
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med, 2017, 377(1): 62-70.
|
| 7. |
Ornes S. Core concept: basket trial approach capitalizes on the molecular mechanisms of tumors. Proc Natl Acad Sci USA, 2016, 113(26): 7007-7008.
|
| 8. |
Park JJH, Hsu G, Siden EG, et al. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin, 2020, 70(2): 125-137.
|
| 9. |
Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med, 2015, 373(8): 726-736.
|
| 10. |
Volovat SR, Ciuleanu TE, Koralewski P, et al. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget, 2020, 11(33): 3105-3117.
|
| 11. |
Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554(7691): 189-194.
|
| 12. |
Simon R, Geyer S, Subramanian J, et al. The Bayesian basket design for genomic variant-driven phase II trials. Semin Oncol, 2016, 43(1): 13-18.
|
| 13. |
Berry SM, Broglio KR, Groshen S, et al. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials, 2013, 10(5): 720-734.
|
| 14. |
Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trials, 2018, 15(2): 149-158.
|
| 15. |
Hobbs BP, Landin R. Bayesian basket trial design with exchangeability monitoring. Stat Med, 2018, 37(25): 3557-3572.
|
| 16. |
郭曉慧, 黃仟, 謝雁鳴, 等. 傘式設計與籃式設計在中醫藥循證評價中的應用. 中國中藥雜志, 2021, 46(8): 2010-2015.
|
| 17. |
胡嘉元, 張曉雨, 趙晨, 等. 母方案設計用于冠心病中醫藥防治方案循證優化的思路和實施方法. 中國循證醫學雜志, 2019, 19(1): 102-106.
|
| 18. |
Hyman DM, Solit DB, Arcila ME, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today, 2015, 20(12): 1422-1428.
|
| 19. |
李涵, 孫楊, 張曉雨, 等. 以證統病—中醫臨床思維的回歸與創新. 世界中醫藥, 2019, 14(10): 2552-2556, 2562.
|
| 20. |
趙晨, 張曉雨, 胡嘉元, 等. 中醫同證候系疾病臨床研究母方案設計方法. 中醫雜志, 2018, 59(2): 111-115.
|
| 21. |
李建生. 基于病證結合模式重視以證統病的診療形式. 中醫雜志, 2011, 52(7): 558-561.
|
| 22. |
黃曉珊. 抗敏鎮咳顆粒治療風咳證異病同治的臨床研究. 南京: 南京中醫藥大學, 2020.
|
| 23. |
Liu W, Zhou L, Feng L, et al. BuqiTongluo granule for ischemic stroke, stable angina pectoris, diabetic peripheral neuropathy with Qi deficiency and blood stasis syndrome: rationale and novel basket design. Front Pharmacol, 2021, 12: 764669.
|
| 24. |
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence-what is it and what can it tell us. N Engl J Med, 2016, 375(23): 2293-2297.
|
| 25. |
楊娜, 趙京紅. 基于中醫理論指導下異病同治(痰瘀互阻證)的臨床研究. 中國實用醫藥, 2014, (26): 245-245, 246.
|
| 26. |
蔣雪峰, 徐雯, 周臘梅. 益腎蠲痹丸治療腰痛的臨床效果觀察. 黑龍江醫藥, 2019, 32(6): 1369-1370.
|
| 27. |
黎鳳儀, 葉婷慧. 止渴降糖方對糖尿病腎病和哮喘的異病同治的臨床療效. 大眾科技, 2021, 23(9): 47-50.
|
| 28. |
關之玥, 劉巖, 張晶晶, 等. 母方案平臺試驗設計方法及其在相關領域中的應用. 中國循證醫學雜志, 2021, 21(8): 986-992.
|
| 29. |
陳凱先. 精準醫學和中醫藥創新發展. 世界科學技術-中醫藥現代化, 2017, 19(1): 7-18.
|